Research programme: human monoclonal antibodies - PDL BioPharma
Latest Information Update: 03 Jul 2006
At a glance
- Originator PDL BioPharma
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Jul 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
- 21 Nov 2003 This programme is still in active development